Diarrhea associated with afatinib: An oral ErbB family blocker

Expert Review of Anticancer Therapy

Volumn 13, Issue 6, 2013, Pages 729-736

  Yang, James Chih Hsin ^a   Reguart, Noemi ^b   Barinoff, Jana ^c   Köhler, Jens ^d   Uttenreuther Fischer, Martina ^e   Stammberger, Uz ^e   O'Brien, Dennis ^f   Wolf, Jürgen ^g   Cohen, Ezra Ew ^h  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b HOSPITAL CLÍNIC   (Spain)

^c Department of Gynecology and Gynecologic Oncology ^*  (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

afatinib; afatinib associated adverse event; diarrhea; EGF receptor; gastrointestinal adverse event

Indexed keywords

AFATINIB; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; LAPATINIB; LOPERAMIDE; NERATINIB; NON PRESCRIPTION DRUG; PLACEBO;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONSTIPATION; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NUTRITIONAL DEFICIENCY; PATIENT EDUCATION; PRACTICE GUIDELINE; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; STOMATITIS; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; DIARRHEA; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84879347777     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.31     Document Type: Review

References (43)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell. Biol. 7(7), 505-516 (2006). (Pubitemid 44036456)
2. Iivanainen E, Elenius K. ErbB targeted drugs and angiogenesis. Curr. Vasc. Pharmacol. 8(3), 421-431 (2010).
3. Rudloff U, Samuels Y. A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 9(8), 1487-1503 (2010).
4. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
5. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in nonsmall cell lung cancer. Lung Cancer 69(1), 1-12 (2010).
6. Licitra L, Bergamini C, Mirabile A, Granata R. Targeted therapy in head and neck cancer. Curr. Opin. Otolaryngol. Head Neck Surg. 19(2), 132-137 (2011).
7. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004). (Pubitemid 38944402)
8. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
9. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011).
10. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
11. Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62(20), 5749-5754 (2002). (Pubitemid 35204731)
12. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57(21), 4838-4848 (1997). (Pubitemid 27468992)
13. Xu Y, Liu H, Chen J, Zhou Q. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol. Ther. 9(8), 572-582 (2010).
14. Gotoh N. Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. Int. J. Clin. Exp. Pathol. 4(4), 403-409 (2011).
15. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711 (2008).
16. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343(2), 342-350 (2012).
17. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
18. Solca F, Schweifer N, Baum A et al. BIBW 2992, an irreversible dual EGFR/HER2 kinase inhibitor, shows activity on L858R/T790M EGFR mutants. Clin. Cancer Res. 11(23), A242 (2005).
19. Eskens FA, Mom CH, Planting AS et al. A Phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 98(1), 80-85 (2008).
20. Murakami H, Tamura T, Takahashi T et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUXLung 4). Cancer Chemother. Pharmacol. 69, 891-899 (2012).
21. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28(25), 3965-3972 (2010).
22. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol. 13, 528-538 (2012).
23. Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a Phase 2 trial. Lancet Oncol. 13, 539-548 (2012).
24. Seiwert TY, Fayette J, Cupissol D et al. A randomized, open-label, Phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck-final data. Presented at: the Multidisciplinary Head and Neck Cancer Symposium. Phoenix, AZ, USA, 26-28 January 2012.
25. Lin NU, Winer EP, Wheatley D et al. A Phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res. Treat. 133(3), 1057-1065 (2012).
26. Ku GY, Haaland BA, de Lima Lopes G Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of Phase III trials. Lung Cancer 74(3), 469-473 (2011).
27. Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr. Oncol. 18(3), 126-138 (2011).
28. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28(8), 1301-1307 (2010).
29. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
30. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005). (Pubitemid 41540110)
31. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008).
32. Crown JP, Burris HA 3rd, Boyle F et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res. Treat. 112(2), 317-325 (2008).
33. Martin M, Bonneterre J, Geyer CE Jr et al. A Phase 2, randomized, open-label, study of neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer. In: the CTRCAACR San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 6-10 December 2011.
34. Uribe JM, Gelbmann CM, Traynor-Kaplan AE, Barrett KE. Epidermal growth factor inhibits Ca(2+)-dependent Cl-transport in T84 human colonic epithelial cells. Am. J. Physiol. 271(3 Pt 1), C914-C922 (1996).
35. Al-Dasooqi N, Gibson R, Bowen J, Keefe D. HER2 targeted therapies for cancer and the gastrointestinal tract. Curr. Drug Targets 10(6), 537-542 (2009).
36. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J. Oncol. 2009, 567486 (2009).
37. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
38. Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a Phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 3076-3083 (2010).
39. Ramalingam SS, Blackhall F, Krzakowski M et al. Randomized Phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 30(27), 3337-3344 (2012).
40. Mok T, Spigel DR, Park K et al. Efficacy and safety of PF299804 as first-line treatment (TX) of patients (PTS) with advanced (ADV) NSCLC selected for activating mutation (MU) of epidermal growth factor receptor (EGFR) Ann. Oncol. 21(Suppl. 8), Abstract LBA18 (2010).
41. Thomas SK, Fossella FV, Liu D et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin. Lung Cancer 7(5), 326-331 (2006). (Pubitemid 43950980)
42. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 45(10), e155-e160 (2009).
43. Benson AB 3rd, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol. 22(14), 2918-2926 (2004). (Pubitemid 41079912)